Profile data is unavailable for this security.
About the company
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
- Revenue in USD (TTM)638.76m
- Net income in USD41.58m
- Incorporated1981
- Employees1.78k
- LocationRepligen CorpBUILDING 1, SUITE 100, 41 SEYON STREETWALTHAM 02453United StatesUSA
- Phone+1 (781) 449-9560
- Fax+1 (302) 655-5049
- Websitehttps://www.repligen.com/
More ▼
Mergers & acquisitions
| Acquired company | RGEN:NSQ since announced | Transaction value |
|---|---|---|
| Metenova AB | 5.53% | -- |
Data delayed at least 15 minutes, as of Apr 26 2024 18:15 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bellring Brands Inc | 1.73bn | 165.20m | 7.24bn | 420.00 | 44.64 | -- | 34.34 | 4.17 | 1.24 | 1.24 | 12.99 | -2.19 | 2.39 | 5.89 | 9.62 | 4,129,762.00 | 22.78 | 18.89 | 29.01 | -- | 32.08 | 32.44 | 9.52 | 10.10 | 1.71 | 4.39 | 1.53 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
| Intra-Cellular Therapies Inc | 464.37m | -139.67m | 7.52bn | 610.00 | -- | 11.75 | -- | 16.19 | -1.46 | -1.46 | 4.84 | 6.14 | 0.6262 | 1.90 | 4.91 | 761,262.30 | -18.84 | -38.27 | -21.89 | -42.77 | 92.73 | -- | -30.08 | -128.42 | 5.31 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Viking Therapeutics Inc | 0.00 | -93.72m | 7.59bn | 28.00 | -- | 8.13 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Cerevel Therapeutics Holdings Inc | 0.00 | -432.84m | 7.64bn | 334.00 | -- | 11.32 | -- | -- | -2.66 | -2.66 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -38.29 | -- | -41.29 | -- | -- | -- | -- | -- | -- | -- | 0.3337 | -- | -- | -- | -23.14 | -- | -- | -- |
| Legend Biotech Corp (ADR) | 285.14m | -518.25m | 8.08bn | 1.80k | -- | 6.46 | -- | 28.34 | -2.95 | -2.95 | 1.62 | 6.88 | 0.1794 | 9.68 | 5.70 | 158,412.80 | -32.60 | -37.71 | -38.89 | -47.19 | 49.42 | -- | -181.75 | -286.51 | 6.83 | -24.23 | 0.208 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Roivant Sciences Ltd | 123.24m | 4.35bn | 8.77bn | 904.00 | 2.15 | 1.44 | 2.06 | 71.14 | 5.07 | 5.23 | 0.1597 | 7.57 | 0.0259 | -- | 3.57 | 136,328.50 | 89.08 | -- | 105.17 | -- | 87.57 | -- | 3,439.02 | -- | 27.77 | -- | 0.0638 | -- | 10.84 | -- | -32.93 | -- | -- | -- |
| KBR Inc | 6.96bn | -265.00m | 8.78bn | 34.00k | -- | 6.37 | -- | 1.26 | -2.03 | -2.03 | 50.04 | 10.24 | 1.25 | -- | 5.91 | 204,588.20 | -4.69 | 0.4725 | -6.77 | 0.6678 | 14.05 | 12.18 | -3.75 | 0.4122 | -- | 1.14 | 0.5679 | 340.00 | 5.97 | 7.20 | -240.21 | -- | 36.31 | 11.03 |
| Repligen Corp | 638.76m | 41.58m | 9.25bn | 1.78k | 229.85 | 4.69 | 84.35 | 14.48 | 0.7207 | 0.7207 | 11.27 | 35.35 | 0.2388 | 1.47 | 5.31 | 358,252.40 | 1.55 | 4.38 | 1.74 | 5.03 | 49.35 | 55.43 | 6.51 | 15.91 | 5.75 | -- | 0.2272 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
| BIO-TECHNE Corp | 1.14bn | 224.12m | 9.85bn | 3.05k | 45.20 | 5.01 | 29.45 | 8.60 | 1.39 | 1.39 | 7.09 | 12.50 | 0.4495 | 2.21 | 5.84 | 375,409.50 | 8.80 | 9.57 | 9.28 | 10.20 | 67.13 | 67.35 | 19.58 | 21.91 | 3.03 | 18.86 | 0.1854 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
| Catalent Inc | 4.10bn | -1.30bn | 10.10bn | 17.80k | -- | 2.74 | -- | 2.46 | -7.18 | -7.18 | 22.52 | 20.37 | 0.3878 | 4.09 | 3.00 | 230,224.70 | -12.32 | 2.88 | -14.02 | 3.26 | 17.94 | 31.03 | -31.77 | 6.35 | 1.71 | -0.625 | 0.5758 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
| Exact Sciences Corp | 2.50bn | -204.15m | 10.67bn | 6.50k | -- | 3.39 | 4,340.06 | 4.27 | -1.14 | -1.14 | 13.81 | 17.34 | 0.3937 | 5.32 | 13.82 | 384,579.40 | -3.22 | -9.71 | -3.47 | -10.60 | 73.83 | 74.10 | -8.17 | -28.21 | 2.07 | -- | 0.4311 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| United Therapeutics Corporation | 2.33bn | 984.80m | 11.10bn | 1.17k | 11.90 | 1.85 | 10.70 | 4.77 | 19.82 | 19.82 | 46.83 | 127.23 | 0.3523 | 2.41 | 9.32 | 1,992,723.00 | 14.91 | 10.38 | 16.33 | 11.27 | 88.94 | 91.47 | 42.31 | 29.25 | 4.28 | -- | 0.1047 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Natera Inc | 1.08bn | -434.80m | 11.16bn | 3.28k | -- | 14.26 | -- | 10.31 | -3.80 | -3.80 | 9.41 | 6.40 | 0.7634 | 15.49 | 4.14 | 329,851.00 | -30.66 | -36.17 | -39.20 | -46.60 | 45.52 | 45.88 | -40.16 | -56.15 | 3.96 | -- | 0.3219 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
| Incyte Corp | 3.70bn | 597.60m | 11.49bn | 2.52k | 19.36 | 2.21 | 16.89 | 3.11 | 2.64 | 2.64 | 16.36 | 23.14 | 0.5855 | 4.43 | 5.32 | 1,464,203.00 | 9.47 | 9.07 | 11.69 | 11.02 | 93.71 | 94.97 | 16.17 | 13.68 | 3.69 | -- | 0.0062 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
Data as of Apr 26 2024. Currency figures normalised to Repligen Corp's reporting currency: US Dollar USD
45.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 5.00m | 8.97% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 4.98m | 8.93% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 3.95m | 7.09% |
| BlackRock Advisors LLCas of 31 Dec 2023 | 1.74m | 3.12% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.70m | 3.06% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 1.65m | 2.96% |
| Macquarie Investment Management Business Trustas of 31 Dec 2023 | 1.57m | 2.81% |
| Brown Capital Management LLCas of 31 Dec 2023 | 1.53m | 2.74% |
| Artisan Partners LPas of 31 Dec 2023 | 1.52m | 2.73% |
| Sands Capital Management LLCas of 31 Dec 2023 | 1.50m | 2.68% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
